Up to 450% mark-up on knee implants, govt may cap prices

  • News
  • August 15, 2017

New Delhi :  Just like stents, the National Pharmaceutical Pricing Authority (NPPA) has revealed the unrealistic trade margins enjoyed by sellers of orthopaedic (knee) implants medical devices . According to the analysis done by the NPPA, the average trade margins on some of the devices used in knee implants are as high as 449 per cent. The total trade margin on five implant components used in the knee range between 211 per cent and 449 per cent. As a result, an insert, which has a landed price of ₹14,071 finally costs the patient ₹1.03 lakh – 449 per cent higher, a price sheet from the NPPA showed. A similar exercise conducted by the Authority before bringing the prices of coronary stents under strict price control, which had shown that between the pharmaceutical company and the patient, trade margins of as much as 1026 per cent were added to the life-saving devices. As a result of which, a stent with a landed cost of about₹40,820 could finally burn a hole worth ₹1.98 lakh in the patient’s pocket. The Authority had finally capped the prices of stents in February, decreasing the maximum retail price by 80 per cent for some devices. It is estimated that over two lakh replacement surgeries are conducted in India and the market is growing at an estimated 26-30 per cent annually.

  • Related Posts

    • News
    • May 27, 2025
    • 212 views
    Ramping Up Community for JeevanRaksha during Disasters

    CBDM India 2025 will Champion Health Resilience and Local Response Bengaluru: As India and its neighbours continue to confront the double threat of increasing natural disasters and unpredictable man-made crises—including…

    • News
    • February 1, 2025
    • 324 views
    Union Budget 2025 pleased Healthcare Leaders except for a Letdown or two

    New Delhi: Healthcare leaders expressed overall satisfaction over Union Budget 2025 except for a letdown or two. Rajiv Nath, Forum Coordinator, Association of Indian Medical Device Industry (AiMeD), though appreciated…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

    Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

    HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

    HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

    ED raids three pharma units in Baddi, Nalagarh

    ED raids three pharma units in Baddi, Nalagarh

    Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

    Glenmark Pharma: FDA concludes inspection at US facility, issues five observations